HYGS News Alert Hydrogenics Corp (HYGS) 12.54 12/12/2014 23:

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 12:10 AM

Hydrogenics Corp (HYGS) 12.54 $HYGS

Solar, fuel cell stocks off sharply after OPEC stands pat
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 9:55AM CST

HYGS: 12.54 (+0.20), RGSE: 0.60 (+0.02), FCEL: 1.62 (+0.03), YGE: 2.27 (-0.03), JASO: 8.51 (-0.38), PLUG: 2.93 (-0.17), TSL: 8.82 (-0.30), HSOL: 1.38 (unch), VSLR: 8.08 (+0.08), TAN: 33.61 (-0.68), SPWR: 23.06 (-0.41), CSIQ: 23.01 (-0.68), JKS: 19.59 (-0.69), BLDP: 1.86 (-0.03), SOL: 1.33 (-0.07), CSUN: 1.28 (+0.03), ENPH: 12.45 (-0.10), FSLR: 42.12 (-0.92), DQ: 24.70 (+0.17), SCTY: 50.02 (-0.89), SUNE: 18.55 (-0.47)

Hydrogenics: Potential Is Still There
Diesel - at Seeking Alpha - Wed Nov 12, 7:22AM CST

HYGS: 12.54 (+0.20)

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CLUB: 6.22 (+0.01), HYGS: 12.54 (+0.20), KNDI: 12.45 (-0.40), MCEP: 6.50 (-0.07), HYG.TO: 14.78 (+0.60), RPRX: 8.74 (+0.26), SHLD: 32.30 (+0.15), PAA.TO: 11.34 (+0.02), PAAS: 9.76 (-0.07), REXX: 5.18 (+0.03), AKBA: 11.33 (+0.25), GCBC: 29.69 (+0.03), ASEI: 47.24 (-1.33), MTEX: 28.10 (-1.00), PLNR: 7.29 (+0.29)

Hydrogenics' (HYGS) CEO Daryl Wilson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 12:22PM CST

HYGS: 12.54 (+0.20)

Hydrogenics (HYGS) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:55AM CST

HYGS: 12.54 (+0.20)

Hydrogenics misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 5:38AM CST

HYGS: 12.54 (+0.20)

Hydrogenics Reports Third Quarter 2014 Results
GlobeNewswire - Mon Nov 10, 5:30AM CST
Hydrogenics Corporation (Nasdaq:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company"

, a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today reported third quarter 2014 financial results. Results are reported in US dollars and are prepared in accordance with International Financial Reporting Standards (IFRS).
HYGS: 12.54 (+0.20), HYG.TO: 14.78 (+0.60)

Hydrogenics to report Q3 results on Nov. 10
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 6:24AM CDT

HYGS: 12.54 (+0.20)

Hydrogenics Announces Third Quarter Conference Call on November 10, 2014
GlobeNewswire - Fri Oct 24, 5:30AM CDT
Hydrogenics Corporation (Nasdaq:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company"

, a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today announced that the Company will host a conference call at 10:00 a.m. Eastern on November 10, 2014 to review the fiscal third quarter and nine months ended September 30, 2014. Earnings will be issued before the market opens, and the filing of the Company's results with the appropriate regulatory bodies will follow.
HYGS: 12.54 (+0.20), HYG.TO: 14.78 (+0.60)

Hydrogenics Introduces "Celerity" Fuel Cell Power System for Medium and Heavy Duty Vehicles
GlobeNewswire - Mon Oct 13, 5:43AM CDT
Hydrogenics Corporation (Nasdaq:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company"

, a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today announced the introduction of "Celerity," a new fuel cell system purposely developed for medium and heavy duty buses and trucks. Celerity provides a distinct solution which will help accelerate the commercialization of zero emission vehicles by reducing the time and cost needed to integrate fuel cells into a vehicle's drivetrain.
HYGS: 12.54 (+0.20), HYG.TO: 14.78 (+0.60)

Hydrogenics Announces Board of Directors Appointment
GlobeNewswire - Thu Oct 02, 5:30AM CDT
Hydrogenics Corporation (Nasdaq:HYGS) (TSX:HYG), a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, announced that Mr. David C. Ferguson has been appointed to the Hydrogenics Board of Directors and its Audit Committee effective immediately.
HYGS: 12.54 (+0.20), HYG.TO: 14.78 (+0.60)

Trade-Ideas: Hydrogenics (HYGS) Is Today's Weak On High Relative Volume Stock
at The Street - Wed Aug 27, 9:00AM CDT
Trade-Ideas LLC identified Hydrogenics (HYGS) as a weak on high relative volume candidate
HYGS: 12.54 (+0.20)

Plug Power (PLUG) Stock Soars on Strong Earnings Beat - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Aug 14, 2:23PM CDT
Shares of Plug Power are rising after a strong earnings report that beat estimates.
HYGS: 12.54 (+0.20), BLDP: 1.86 (-0.03), PLUG: 2.93 (-0.17), WMT: 83.81 (-0.02)

Hydrogenics Announces Upcoming Investor Events
GlobeNewswire - Thu Jul 31, 5:29AM CDT
Hydrogenics Corporation (Nasdaq:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company"

, a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today announced that the Company will participate in the following investor events. Institutional investors are welcome to attend and meet with management.
HYGS: 12.54 (+0.20), HYG.TO: 14.78 (+0.60)

Hydrogenics Reports Second Quarter 2014 Results
GlobeNewswire - Wed Jul 30, 5:30AM CDT
Hydrogenics Corporation (Nasdaq:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company"

, a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today reported second quarter 2014 financial results. Results are reported in US dollars and are prepared in accordance with International Financial Reporting Standards (IFRS).
HYGS: 12.54 (+0.20), HYG.TO: 14.78 (+0.60)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...